Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial

Table 1 The mean and standard deviation of the baseline characteristics of type 2 diabetes patients

Variable	Category	Group		P-value
Variable	Category	Vitamin D (N = 42)	Placebo (N = 43)	P-value
Age (Y)	–	50.36 (10.2)	50.05 (10.7)	0.892^*
Weight (kg)	–	77.38 (10.9)	79.27 (11.6)	0.442^*
Height (cm)	–	159.35 (8.0)	158.77 (7.6)	0.736^*
BMI (kg/m ²⁾)	–	30.43 (3.2)	31.37 (3.4)	0.194^*
Disease duration (months)	–	65.52 (38.5)	67.02 (35.4)	0.664^*
Medications (per day)	Metformin (500 mg/d)	2.11 (1.13)	2.51 (1.26)	0.135^*
Medications (per day)	Glibenclamide (5 mg/d)	1.31 (0.94)	0.95 (0.78)	0.135^*
Gender	Male	7.00 (16.7)	8.00 (18.6)	0.815**
Gender	Female	35.00 (83.3)	35.00 (81.4)	0.815**
Employment status	Unemployed	32.00 (76.2)	32.00 (74.4)	0.850**
Employment status	employed	10.00 (23.8)	11.00 (25.6)	0.850**

*Independent t-test; **Chi-square test, Y Year, kg Kilogram, cm Centimeter, BMI Body mass index, mg Milligram

ISSN: 2731-4553